Pulmonary Arterial Hypertension in a Patient With Metastatic Lung Cancer on Pembrolizumab: Whom to Blame?

Authors

  • Lakshmi Manogna Chintalacheruvu
  • Vamsi Krishna Chilluru
  • Narendra Babu Gutta

DOI:

https://doi.org/10.14740/jmc5115

Keywords:

Pulmonary hypertension, Immune checkpoint inhibitors, Pembrolizumab, Lung cancer, Pulmonary artery diameter, Aorta diameter

Abstract

Immune checkpoint inhibitors (ICIs) play a major role in current cancer treatments. They are associated with immune-mediated side effects due to immune dysregulation. ICI-mediated complications are more commonly known to affect thyroid gland, gastrointestinal system, skin, etc. Pulmonary arterial hypertension (PAH) due to ICIs is not very well described in the literature. Here, we report a case of severe PAH diagnosed in a patient with metastatic lung cancer on long-term pembrolizumab and literature review.

Author Biographies

  • Lakshmi Manogna Chintalacheruvu, Southern Illinois Health

    Hematology/Oncology, Southern Illinois Health Cancer Institute, Carterville, Illinois, United

    States of America

  • Vamsi Krishna Chilluru

    Nephrology, Southern Illinois Health

  • Narendra Babu Gutta

    Interventional Radiology, Cape Radiology Group

Downloads

Published

2025-04-26

Issue

Vol. 16, No. 4, Apr 2025

Section

Case Report

License

Copyright (c) 2025 The authors

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

How to Cite

1.
Chintalacheruvu LM, Chilluru VK, Gutta NB. Pulmonary Arterial Hypertension in a Patient With Metastatic Lung Cancer on Pembrolizumab: Whom to Blame?. J Med Cases. 2025;16(4):153-157. doi:10.14740/jmc5115